Kura Oncology KURA
NASDAQ KURA
$9.81 -0.07 (-0.71%)
As of: Oct 22, 2026 · 12:55 PM EDT

Kura Oncology (KURA) FCF Margin (2025 - 2026)

Updated

Kura Oncology (KURA) reported FCF Margin of -302.79% for Q2 2026, down 105.02 percentage points from -197.77% a year earlier but up 167.95 percentage points from the prior quarter.

Analysis

Kura Oncology (KURA) FCF Margin (2025 - 2026) Analysis & Trends

Over the twelve months ended Jun 30, 2026, Kura Oncology's FCF Margin came in at -152.06%; for FY2025, it was -104.76%, down 353.16 percentage points from FY2024.

  • By year, FCF Margin came in at 248.40% in FY2024.
  • Five-year quarterly FCF Margin spans a low of -511.90% in Q1 2025 and a high of 663.08% in Q4 2025.
  • Per Business Quant data, the three quarters before Q2 2026 came in at -470.75% (Q1 2026), 663.08% (Q4 2025) and -400.93% (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) FCF Margin (Qtr)
1 Eli Lilly 1,168.10 Bn 1,136.68 Bn 19.71 Bn 33.76%
2 Johnson & Johnson 643.43 Bn 561.95 Bn 17.26 Bn 28.82%
3 AbbVie 500.92 Bn 474.03 Bn 12.70 Bn 18.33%
4 Merck 360.47 Bn 314.85 Bn 12.21 Bn 26.96%
5 Novartis Ag 302.41 Bn 266.40 Bn 11.24 Bn 38.60%
6 Astrazeneca 267.36 Bn 241.05 Bn 12.86 Bn 6.55%
7 Amgen 241.30 Bn 196.70 Bn 7.24 Bn 34.70%
8 Gilead Sciences 192.97 Bn 167.17 Bn 6.22 Bn 44.00%
9 Pfizer 171.65 Bn 118.30 Bn 10.94 Bn 2.01%
10 Kura Oncology 866.78 Mn -1.45 Bn 20.63 Mn -302.79%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -302.79%
Mar 31, 2026 -470.75%
Dec 31, 2025 663.08%
Sep 30, 2025 -400.93%
Jun 30, 2025 -197.77%
Mar 31, 2025 -511.90%
API Access

Kura Oncology FCF Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=fcf-margin&ticker=KURA&period=max&api_key=YOUR_API_KEY